[go: up one dir, main page]

PE20150362A1 - Metodo de identificacion de factores de riesgo de la enfermedad - Google Patents

Metodo de identificacion de factores de riesgo de la enfermedad

Info

Publication number
PE20150362A1
PE20150362A1 PE2015000030A PE2015000030A PE20150362A1 PE 20150362 A1 PE20150362 A1 PE 20150362A1 PE 2015000030 A PE2015000030 A PE 2015000030A PE 2015000030 A PE2015000030 A PE 2015000030A PE 20150362 A1 PE20150362 A1 PE 20150362A1
Authority
PE
Peru
Prior art keywords
disease
identification
genetic variant
kits
interest
Prior art date
Application number
PE2015000030A
Other languages
English (en)
Inventor
Allen D Roses
Original Assignee
Zinfandel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150362(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zinfandel Pharmaceuticals Inc filed Critical Zinfandel Pharmaceuticals Inc
Publication of PE20150362A1 publication Critical patent/PE20150362A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La invencion proporciona un metodo para la identificacion de una variante genetica que esta asociada con el desarrollo de un padecimiento de interes (por ejemplo, la enfermedad de Alzheimer), y las variantes geneticas identificadas de esta manera. Tambien se proporcionan metodos de tratamiento con un ingrediente activo (por ejemplo, con un agente activo particular y/o en una etapa mas temprana), al momento de detectar una variante genetica aqui descrita. En algunas modalidades, la variante genetica es un polimorfismo de eliminacion/insercion (DIP) del gen TOMM40. Tambien se proporcionan los equipos para determinar si un sujeto se encuentra en un riesgo aumentado de desarrollar la enfermedad de Alzheimer de presentacion tardia. Ademas se proporcionan equipos para determinar si un sujeto actua en respuesta al tratamiento para un padecimiento de interes con un agente activo.
PE2015000030A 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad PE20150362A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8820308P 2008-08-12 2008-08-12
US18667309P 2009-06-12 2009-06-12
US22464709P 2009-07-10 2009-07-10

Publications (1)

Publication Number Publication Date
PE20150362A1 true PE20150362A1 (es) 2015-03-20

Family

ID=41669605

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2015000030A PE20150362A1 (es) 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad
PE2011000157A PE20110565A1 (es) 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad
PE2015002280A PE20151924A1 (es) 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2011000157A PE20110565A1 (es) 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad
PE2015002280A PE20151924A1 (es) 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad

Country Status (32)

Country Link
US (4) US8815508B2 (es)
EP (2) EP2324126B1 (es)
JP (4) JP5833922B2 (es)
KR (3) KR20180053432A (es)
CN (3) CN102177436B (es)
AU (3) AU2009282114B2 (es)
BR (1) BRPI0917948A2 (es)
CA (1) CA2735578C (es)
CL (1) CL2011000298A1 (es)
CO (1) CO6351823A2 (es)
CY (1) CY1115412T1 (es)
DK (1) DK2324126T3 (es)
DO (1) DOP2011000052A (es)
EA (1) EA021399B1 (es)
ES (1) ES2463766T3 (es)
GE (1) GEP20146107B (es)
HK (1) HK1153511A1 (es)
HR (1) HRP20140709T1 (es)
IL (2) IL211140A (es)
MA (1) MA32619B1 (es)
ME (1) ME01898B (es)
MX (1) MX2011001671A (es)
NZ (3) NZ591107A (es)
PE (3) PE20150362A1 (es)
PL (1) PL2324126T3 (es)
PT (1) PT2324126E (es)
RS (1) RS53383B (es)
SG (1) SG193793A1 (es)
SI (1) SI2324126T1 (es)
SM (1) SMT201400088B (es)
WO (1) WO2010019550A2 (es)
ZA (1) ZA201101095B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
PE20150362A1 (es) 2008-08-12 2015-03-20 Zinfandel Pharmaceuticals Inc Metodo de identificacion de factores de riesgo de la enfermedad
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
EP3657507A1 (en) 2010-05-25 2020-05-27 The Regents of The University of California Bambam: parallel comparative analysis of high-throughput sequencing data
AU2013204020B2 (en) * 2011-01-10 2016-03-31 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
AU2011354696B2 (en) * 2011-01-10 2015-03-05 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CA2824050A1 (en) 2011-01-10 2012-07-19 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
US20120231457A1 (en) * 2011-03-10 2012-09-13 Nikolaos Tezapsidis Compositions and methods for assessing a genetic risk of developing late-onset alzheimer's disease (load)
US8718950B2 (en) 2011-07-08 2014-05-06 The Medical College Of Wisconsin, Inc. Methods and apparatus for identification of disease associated mutations
US20130080182A1 (en) * 2011-09-26 2013-03-28 Athleticode Inc. Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury
WO2013106084A1 (en) * 2012-01-09 2013-07-18 Takeda Pharmaceutical Company Limited Methods and drug products for treating alzheimer's disease
GB201209689D0 (en) * 2012-05-31 2012-07-18 Imp Innovations Ltd Methods
US10586612B2 (en) 2013-03-01 2020-03-10 Actx, Inc. Cloud-like medical-information service
WO2015174544A1 (ja) * 2014-05-16 2015-11-19 国立研究開発法人国立精神・神経医療研究センター 精神疾患判定マーカー
EP3325654B1 (en) 2015-07-23 2020-06-10 Asuragen, Inc. Methods, compositions, kits, and uses for analysis of nucleic acids comprising repeating a/t-rich segments
JP7475811B2 (ja) 2016-05-20 2024-04-30 シーダーズ―シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
CN105969885A (zh) * 2016-06-24 2016-09-28 江苏雄鸣医药科技有限公司 一种阿尔兹海默症的基因诊断试剂盒
US11352625B2 (en) 2017-01-12 2022-06-07 Duke University Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease
EP3599842B1 (en) * 2017-03-21 2024-08-07 The Jackson Laboratory A genetically modified mouse expressing human apoe4 and mouse trem2.p.r47h and methods of use thereof
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
MX2020001325A (es) * 2017-07-31 2020-07-13 Quest Diagnostics Invest Llc Deteccion de isotipo de apolipoproteina e mediante espectrometria de masas.
JP2021501415A (ja) * 2017-10-31 2021-01-14 ジーイー・ヘルスケア・リミテッド 認知症の病理学および／または転帰を診断するための医療システム
CN112805785A (zh) * 2018-01-31 2021-05-14 卡尔莱特股份有限公司 提高患者生活质量、参与度和持续性的疾病因子的早期反馈
KR102303638B1 (ko) * 2018-04-13 2021-09-23 사회복지법인 삼성생명공익재단 알츠하이머성 치매가 발병될 가능성 평가방법
WO2019215085A1 (en) 2018-05-07 2019-11-14 Biotx.Ai Gmbh Method for predicting the risk of late-onset alzheimer's diseases
US20220226278A1 (en) * 2018-05-18 2022-07-21 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
EP3626835A1 (en) * 2018-09-18 2020-03-25 Sistemas Genómicos, S.L. Method for genotypically identifying both alleles of at least one locus of a subject's hla gene
KR102127903B1 (ko) * 2019-01-29 2020-06-29 연세대학교 산학협력단 염증성 호흡기 질환의 진단용 바이오마커
EP3976829A4 (en) * 2019-05-30 2023-07-12 PolygenRx Pty Ltd METHOD OF TREATMENT OR PROPHYLAXIS
CN111593107A (zh) * 2020-01-15 2020-08-28 丁玎 阿尔兹海默症易感位点rs10119与rs71352238的检测方法及试剂盒
CN111187825A (zh) * 2020-01-15 2020-05-22 丁玎 阿尔兹海默症的tomm40基因及apoe基因的易感位点的检测方法及试剂盒
KR102535235B1 (ko) * 2020-11-25 2023-05-26 서울대학교산학협력단 알츠하이머병 발병 위험도 예측을 위한 단일염기다형성 마커 및 이의 용도
RU2757522C1 (ru) * 2021-06-02 2021-10-18 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) СПОСОБ ПРОГНОЗИРОВАНИЯ РАЗВИТИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 1 и 2 ТИПА (варианты)
KR102770667B1 (ko) * 2022-04-22 2025-02-21 사회복지법인 삼성생명공익재단 유럽-동아시아인 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US663780A (en) * 1898-09-09 1900-12-11 Wheeler & Wilson Mfg Co Trimming attachment for sewing-machines.
US4302204A (en) 1979-07-02 1981-11-24 The Board Of Trustees Of Leland Stanford Junior University Transfer and detection of nucleic acids
US4358535A (en) 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
FI63596C (fi) 1981-10-16 1983-07-11 Orion Yhtymae Oy Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser
US4994373A (en) 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US6060237A (en) 1985-02-26 2000-05-09 Biostar, Inc. Devices and methods for optical detection of nucleic acid hybridization
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5112460A (en) * 1986-10-21 1992-05-12 Northeastern University High performance microcapillary gel electrophoresis
DE3856378T2 (de) 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
US5595883A (en) * 1990-06-01 1997-01-21 E. R. Squibb & Sons, Inc. Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid
US5171750A (en) * 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
TW263504B (es) 1991-10-03 1995-11-21 Pfizer
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
EP0587377A3 (en) * 1992-09-10 1994-09-21 Lilly Co Eli Thiazolidinone derivatives as hypoglycemic agents and for treating alzheimer's disease
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
US6128587A (en) 1997-01-14 2000-10-03 The Regents Of The University Of California Method and apparatus using Bayesian subfamily identification for sequence analysis
US5904824A (en) * 1997-03-07 1999-05-18 Beckman Instruments, Inc. Microfluidic electrophoresis device
DE69838789T2 (de) * 1997-03-12 2008-10-30 Suzanne Cambridge de la Monte Verfahren zur behandlung oder prävention der alzheimerischen krankheit
DE69809827D1 (de) * 1997-03-31 2003-01-16 Korea Res Inst Chem Tech Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
ATE325607T1 (de) * 1997-11-19 2006-06-15 Takeda Pharmaceutical Aptoptoseinhibitoren
US6964868B1 (en) 1998-01-28 2005-11-15 Nuvelo, Inc. Human genes and gene expression products II
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
JP2002534055A (ja) 1998-05-14 2002-10-15 カイロン コーポレイション ヒト遺伝子および遺伝子発現産物ｖ
AU4529299A (en) 1998-06-16 2000-01-05 Variagenics, Inc. Methods for treating a neurological disease by determining bche genotype
WO2000020634A1 (en) 1998-10-01 2000-04-13 Nova Molecular, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
EP1129216B1 (en) 1998-11-10 2004-09-08 Genset Methods, software and apparati for identifying genomic regions harboring a gene associated with a detectable trait
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
CN1078616C (zh) * 1998-12-16 2002-01-30 中国科学院上海生命科学研究中心 一种检测样品中是否存在老年痴呆病基因的方法和试剂盒
JP2000273040A (ja) * 1999-01-19 2000-10-03 Sankyo Co Ltd トログリタゾンを含有するアポトーシス抑制剤
US6401043B1 (en) * 1999-04-26 2002-06-04 Variagenics, Inc. Variance scanning method for identifying gene sequence variances
JP2002543118A (ja) 1999-04-29 2002-12-17 シティ・オブ・ホープ ペントキシフィリン、ピオグリタゾンおよびメトフォルミンは、後期糖化最終生成物（ａｇｅ）の形成の阻害剤である
US6573049B1 (en) 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
DE19936719A1 (de) 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte 1,5-Dihydropyrrol-2-on-Derivate
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6532467B1 (en) 2000-04-10 2003-03-11 Sas Institute Inc. Method for selecting node variables in a binary decision tree structure
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
AU1313602A (en) * 2000-10-11 2002-04-22 Esperion Therapeutics Inc Ketone compounds and compositions for cholesterol management and related uses
MXPA03003022A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de sulfuro y disulfuro y composiciones para el control del colesterol y usos relacionados.
CA2425678A1 (en) 2000-10-11 2002-04-18 Jean-Louis H. Dasseux Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US20040122091A1 (en) 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
IL156015A0 (en) 2000-11-24 2003-12-23 Vascular Biogenics Ltd Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6495335B2 (en) 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US6828462B2 (en) 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US7132244B2 (en) * 2001-11-21 2006-11-07 Syn X Pharma, Inc. Betaine/GABA transport protein biopolymer marker indicative of insulin resistance
US7052849B2 (en) 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US7135297B2 (en) 2001-11-23 2006-11-14 Nanogen Inc. Protein biopolymer markers indicative of insulin resistance
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
JPWO2004005510A1 (ja) 2002-07-05 2005-11-04 塩野義製薬株式会社 新規Ｎｏｇｏ受容体様ポリペプチドおよびそのＤＮＡ
US20040265849A1 (en) * 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
WO2004075010A2 (en) * 2003-02-14 2004-09-02 Intergenetics Incorporated Statistically identifying an increased risk for disease
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
WO2005003766A2 (en) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
JP4931419B2 (ja) 2003-09-19 2012-05-16 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
US20050277129A1 (en) 2004-01-22 2005-12-15 Genaissance Pharmaceuticals APOE genetic markers associated with age of onset of Alzheimer's disease
TW200538738A (en) 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
WO2006054297A2 (en) 2004-11-17 2006-05-26 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006083854A2 (en) * 2005-01-31 2006-08-10 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EA200800880A1 (ru) 2005-09-22 2009-02-27 Смитклайн Бичам (Корк) Лимитед Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
US7608412B2 (en) 2005-10-05 2009-10-27 Auburn University P62 as a diagnostic tool for alzheimer's disease
EP2486926A1 (en) 2006-03-16 2012-08-15 Metabolic Solutions Development Company LLC Thiazolidinedione Analogues
US20080045582A1 (en) 2006-05-15 2008-02-21 Issam Zineh ENA-78 Gene Polymorphisms and Protein Concentrations as Diagnostic and Prognostic Tools
EP2037948B1 (en) 2006-05-30 2016-04-13 Mayo Foundation For Medical Education And Research Detecting and treating dementia
US7651840B2 (en) * 2006-07-14 2010-01-26 Celera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
EP2066355A2 (en) 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20090042849A1 (en) 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
US7794937B2 (en) 2006-12-22 2010-09-14 Quest Diagnostics Investments Incorporated Cystic fibrosis transmembrane conductance regulator gene mutations
GB0702537D0 (en) 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US20080286876A1 (en) 2007-05-14 2008-11-20 Chissoe Stephanie GENES ASSOCIATED WITH ALZHEIMER'S DISEASE - Hltdip
US8652508B2 (en) 2007-05-25 2014-02-18 Children's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
TW200914006A (en) 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
US8846315B2 (en) * 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
PE20150362A1 (es) * 2008-08-12 2015-03-20 Zinfandel Pharmaceuticals Inc Metodo de identificacion de factores de riesgo de la enfermedad
US20100136584A1 (en) 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2010066901A2 (en) 2008-12-12 2010-06-17 Poxel Tetrahydrotriazine compounds for treating diseases associated with ampk activity
EP2391374B1 (en) 2009-02-02 2018-11-14 Laila Nutraceuticals Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
JP5882196B2 (ja) 2009-04-23 2016-03-09 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． アディポネクチン受容体フラグメントの単量体及び二量体形態ならびに使用の方法
CA2709621A1 (en) 2009-09-11 2011-03-11 Electrophoretics Limited Markers and methods relating to the assessment of alzheimer's disease
US8293537B2 (en) 2010-02-10 2012-10-23 Selinfreund Richard H Systems and methods for hemoglobin analysis
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
CA2824050A1 (en) * 2011-01-10 2012-07-19 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease

Also Published As

Publication number Publication date
AU2009282114A1 (en) 2010-02-18
ES2463766T3 (es) 2014-05-29
EP2324126A4 (en) 2012-05-30
CY1115412T1 (el) 2017-01-04
AU2018202373A1 (en) 2018-04-26
HK1153511A1 (en) 2012-03-30
CN104805198B (zh) 2019-04-26
US20110189165A1 (en) 2011-08-04
DOP2011000052A (es) 2011-04-15
RS53383B (en) 2014-10-31
SMT201400088B (it) 2014-09-08
JP2018075005A (ja) 2018-05-17
MX2011001671A (es) 2011-06-17
CL2011000298A1 (es) 2012-07-13
HRP20140709T1 (hr) 2014-09-26
ME01898B (me) 2014-12-20
JP2019076095A (ja) 2019-05-23
JP2012500004A (ja) 2012-01-05
EP2789695A1 (en) 2014-10-15
SI2324126T1 (sl) 2014-07-31
CA2735578A1 (en) 2010-02-18
NZ591107A (en) 2012-08-31
PE20110565A1 (es) 2011-09-02
AU2009282114A2 (en) 2011-04-28
PL2324126T3 (pl) 2014-09-30
WO2010019550A4 (en) 2011-01-13
NZ710443A (en) 2019-03-29
IL211140A (en) 2015-06-30
KR20110063453A (ko) 2011-06-10
US20180363060A1 (en) 2018-12-20
DK2324126T3 (da) 2014-06-16
EP2324126A2 (en) 2011-05-25
US8815508B2 (en) 2014-08-26
MA32619B1 (fr) 2011-09-01
US20210095345A1 (en) 2021-04-01
EP2789695B1 (en) 2019-10-30
KR101729340B1 (ko) 2017-04-24
CN102177436B (zh) 2015-05-13
BRPI0917948A2 (pt) 2017-06-20
KR20160127181A (ko) 2016-11-02
CA2735578C (en) 2018-10-23
JP2016047058A (ja) 2016-04-07
GEP20146107B (en) 2014-06-10
NZ619895A (en) 2015-12-24
CN104611421A (zh) 2015-05-13
CO6351823A2 (es) 2011-12-20
KR20180053432A (ko) 2018-05-21
CN104611421B (zh) 2018-08-07
AU2016204678A1 (en) 2016-07-21
SG193793A1 (en) 2013-10-30
IL239277A0 (en) 2015-07-30
PT2324126E (pt) 2014-06-02
EA021399B1 (ru) 2015-06-30
WO2010019550A3 (en) 2010-04-22
EA201170332A1 (ru) 2011-10-31
ZA201101095B (en) 2012-07-25
US20150073025A1 (en) 2015-03-12
IL211140A0 (en) 2011-04-28
JP5833922B2 (ja) 2015-12-16
CN102177436A (zh) 2011-09-07
EP2324126B1 (en) 2014-04-23
PE20151924A1 (es) 2016-01-13
AU2009282114B2 (en) 2016-04-07
WO2010019550A2 (en) 2010-02-18
US10865449B2 (en) 2020-12-15
CN104805198A (zh) 2015-07-29
AU2016204678B2 (en) 2018-04-19
JP6815372B2 (ja) 2021-01-20

Similar Documents

Publication Publication Date Title
PE20150362A1 (es) Metodo de identificacion de factores de riesgo de la enfermedad
CO6331372A2 (es) Inhibidor de parp 4-yodo-3-nitrobenzamida o un metabolito de la misma
CO2021009163A2 (es) Composiciones de agente de arni de proteína precursora de amiloide (app) y método de uso de las mismas
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
CR9686A (es) Metodo para la prediccion de la respuesta a un tratamiento
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
CY1118335T1 (el) Συνθεσεις και μεθοδοι για τον ελεγχο παρασιτικων ακαρεων στις μελισσες
BRPI0710123A2 (pt) Previsão de heterose e outros traços por análise de transcriptoma.
CR11031A (es) Composiciones de enzima digestiva estable
CY1112579T1 (el) Μεθοδοι και συνθεσεις για τη διαγνωση του ηλικιακου εκφυλισμου της ωχρας κηλιδας
Márquez-Ruiz et al. Usefulness of telomere length in DNA from human teeth for age estimation
ECSP056189A (es) Composiciones y método para el tratamiento de infecciones en ganado vacuno y porcino
AR058749A1 (es) Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento
NI201100025A (es) Métodos de administración de las formulaciones tópicas antimicóticas para el tratamiento de las infecciones por hongos.
AR064509A1 (es) Promotores inducibles por el gen peroxidasa del nematodo y metodos de uso
TW200833842A (en) Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
AR064269A1 (es) Formulaciones inhalantes de bisfosfonato y metodos para su utilizacion
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
BR112017019620A2 (pt) ?roedor geneticamente modificado, célula ou tecido, métodos para produção de um roedor geneticamente modificado e de uma população de neurônios motores, métodos para seleção de um agente candidato para modular a disfunção neuronal motora e de um agente candidato para redução do estresse oxidativo em um neurônio motor, ácido nucleico, e, célula de roedor?
ECSP11010884A (es) Método de identificación de factores de riesgo de la enfermedad
ATE432997T1 (de) Therapieüberwachung für tumoren unter benutzung acc133 mrna
ES2674053T3 (es) Diagnóstico de paraplejias espásticas hereditarias (HPS) a través de la identificación de una mutación en el gen o proteína ZFYVE26
MX358594B (es) Factores de riesgo de enfermedad y métodos de uso.
ES2419059T3 (es) Evaluación del efecto de un agente en un estado biológico humano usando paneles de expresión génica de roedores

Legal Events

Date Code Title Description
FC Refusal